Jessica Hope Roark

Array ( [id] => 10149072 [patent_doc_number] => 09181349 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-10 [patent_title] => 'Dual variable region antibody-like binding proteins having cross-over binding region orientation' [patent_app_type] => utility [patent_app_number] => 13/826126 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 26965 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13826126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330113 [patent_doc_number] => 20140056895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation' [patent_app_type] => utility [patent_app_number] => 13/804965 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 26792 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13804965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408982 [patent_doc_number] => 09556274 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/778984 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 190 [patent_no_of_words] => 76980 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13778984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408982 [patent_doc_number] => 09556274 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/778984 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 190 [patent_no_of_words] => 76980 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13778984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548520 [patent_doc_number] => 09273130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Pharmaceutical composition for treatment and/or prevention of cancer' [patent_app_type] => utility [patent_app_number] => 14/379876 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18700 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14379876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9805227 [patent_doc_number] => 20150017172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-15 [patent_title] => 'PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/379867 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19135 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14379867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864202 [patent_doc_number] => 20150044221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/379868 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18597 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14379868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9034293 [patent_doc_number] => 20130236931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-12 [patent_title] => 'SEQUENCE DIVERSITY GENERATION IN IMMUNOGLOBULINS AND OTHER PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/765484 [patent_app_country] => US [patent_app_date] => 2013-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 26941 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13765484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11177991 [patent_doc_number] => 09409976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-09 [patent_title] => 'CDIM binding proteins and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/763398 [patent_app_country] => US [patent_app_date] => 2013-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 14549 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13763398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001462 [patent_doc_number] => 09045541 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'CD47 antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 13/761087 [patent_app_country] => US [patent_app_date] => 2013-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 33 [patent_no_of_words] => 33214 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13761087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8927547 [patent_doc_number] => 20130183307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-18 [patent_title] => 'ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY' [patent_app_type] => utility [patent_app_number] => 13/739974 [patent_app_country] => US [patent_app_date] => 2013-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14542 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13739974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892454 [patent_doc_number] => 20130165638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'LIGHT CHAIN-BRIDGED BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/728839 [patent_app_country] => US [patent_app_date] => 2012-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 7033 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13728839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8964362 [patent_doc_number] => 20130203964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'ANTIBODY DERIVATIVES' [patent_app_type] => utility [patent_app_number] => 13/725712 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 11400 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13725712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8791721 [patent_doc_number] => 20130108690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'ANTI-APOPTOTIC PROTEIN ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/719335 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 12283 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13719335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10953337 [patent_doc_number] => 20140356358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/367183 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 43838 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14367183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9778162 [patent_doc_number] => 08853369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-07 [patent_title] => 'Anti-Axl antibodies and methods of use' [patent_app_type] => utility [patent_app_number] => 13/708685 [patent_app_country] => US [patent_app_date] => 2012-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 39 [patent_no_of_words] => 44388 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13708685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001467 [patent_doc_number] => 09045546 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Molecules and methods for modulating TMEM16A activities' [patent_app_type] => utility [patent_app_number] => 13/690269 [patent_app_country] => US [patent_app_date] => 2012-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 29965 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13690269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11415292 [patent_doc_number] => 09562110 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-07 [patent_title] => 'Bispecific antibody' [patent_app_type] => utility [patent_app_number] => 14/119179 [patent_app_country] => US [patent_app_date] => 2012-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 24 [patent_no_of_words] => 20457 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14119179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8720704 [patent_doc_number] => 20130071921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-21 [patent_title] => 'ANTIBODIES SPECIFIC FOR DKK-1 AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 13/680569 [patent_app_country] => US [patent_app_date] => 2012-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 56451 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13680569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8791612 [patent_doc_number] => 20130108581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic Agents' [patent_app_type] => utility [patent_app_number] => 13/679374 [patent_app_country] => US [patent_app_date] => 2012-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4998 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13679374 [rel_patent_id] =>[rel_patent_doc_number] =>)